{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:03:29Z","timestamp":1793916209464,"version":"4.8.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>High-count monoclonal B-cell lymphocytosis (HCMBL) is a precursor condition to chronic lymphocytic leukemia (CLL). We have shown that among individuals with HCMBL, the CLL-International Prognostic Index (CLL-IPI) is prognostic for time-to-first therapy (TTFT). Little is known about the prognostic impact of somatically mutated genes among individuals with HCMBL. We sequenced DNA from 371 individuals with HCMBL using a targeted sequencing panel of 59 recurrently mutated genes in CLL to identify high-impact mutations. We compared the sequencing results with that of our treatment-na\u00efve CLL cohort (N\u00a0= 855) and used Cox regression to estimate hazard ratios and 95% confidence intervals (CIs) for associations with TTFT. The frequencies of any mutated genes were lower in HCMBL (52%) than CLL (70%). At 10 years, 37% of individuals with HCMBL with any mutated gene had progressed requiring treatment compared with 10% among individuals with HCMBL with no mutations; this led to 5.4-fold shorter TTFT (95%\u00a0CI, 2.6-11.0) among HCMBL with any mutated gene vs none, independent of CLL-IPI. When considering individuals with low risk of progression according to CLL-IPI, those with HCMBL with any mutations had 4.3-fold shorter TTFT (95%\u00a0CI, 1.6-11.8) vs those with none. Finally, when considering both CLL-IPI and any mutated gene status, we observed individuals with HCMBL who were high risk for both prognostic factors had worse prognosis than patients with low-risk CLL (ie, 5-year progression rate of 32% vs 21%, respectively). Among HCMBL, the frequency of somatically mutated genes at diagnosis is lower than that of CLL. Accounting for both the number of mutated genes and CLL-IPI can identify individuals with HCMBL with more aggressive clinical course.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012242","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T20:54:56Z","timestamp":1708030496000},"page":"2118-2129","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-0421","authenticated-orcid":false,"given":"Geffen","family":"Kleinstern","sequence":"first","affiliation":[{"name":"1School of Public Health, University of Haifa, Haifa, Israel"},{"name":"2Division of Computational Biology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-2072","authenticated-orcid":false,"given":"Nicholas J.","family":"Boddicker","sequence":"additional","affiliation":[{"name":"2Division of Computational Biology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"2Division of Computational Biology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Allmer","sequence":"additional","affiliation":[{"name":"3Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7313-1875","authenticated-orcid":false,"given":"Kari G.","family":"Rabe","sequence":"additional","affiliation":[{"name":"3Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Norman","sequence":"additional","affiliation":[{"name":"4Division of Epidemiology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-8861","authenticated-orcid":false,"given":"Rosalie","family":"Griffin","sequence":"additional","affiliation":[{"name":"2Division of Computational Biology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihuang","family":"Yan","sequence":"additional","affiliation":[{"name":"2Division of Computational Biology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[{"name":"2Division of Computational Biology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Call","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bruins","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sochilt","family":"Brown","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Bonolo de Campos","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"7Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-9322","authenticated-orcid":false,"given":"Celine M.","family":"Vachon","sequence":"additional","affiliation":[{"name":"4Division of Epidemiology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Oakes","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"9The Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Parker","sequence":"additional","affiliation":[{"name":"10College of Medicine, University of Florida, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Duke University, Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Brice","family":"Weinberg","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Duke University, Duke Cancer Institute, Durham, NC"},{"name":"12Department of Immunology, Duke University Medical Center, Durham, NC"},{"name":"13Durham Veterans Affairs Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[{"name":"14Weill Cornell Medical College\/New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait D.","family":"Shanafelt","sequence":"additional","affiliation":[{"name":"15Department of Medicine, Division of Hematology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"4Division of Epidemiology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3860-4830","authenticated-orcid":false,"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4712","authenticated-orcid":false,"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[{"name":"2Division of Computational Biology, Mayo Clinic, Rochester, MN"},{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"issue":"7","key":"2024051415211690800_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMoa0806122","article-title":"B-cell clones as early markers for chronic lymphocytic leukemia","volume":"360","author":"Landgren","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2024051415211690800_bib2","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.2020006322","article-title":"Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families","volume":"137","author":"Slager","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2024051415211690800_bib3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood.2021012890","article-title":"High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis","volume":"139","author":"Kolijn","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024051415211690800_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"Br J Haematol"},{"issue":"25","key":"2024051415211690800_bib5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2024051415211690800_bib6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/leu.2009.287","article-title":"Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management","volume":"24","author":"Shanafelt","year":"2010","journal-title":"Leukemia"},{"key":"2024051415211690800_bib7","first-page":"S19","article-title":"Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL)","volume":"78 Suppl 1","author":"Rawstron","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"2024051415211690800_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1056\/NEJMoa075290","article-title":"Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"359","author":"Rawstron","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024051415211690800_bib9","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.2008.21.2704","article-title":"Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia","volume":"27","author":"Shanafelt","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024051415211690800_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07711.x","article-title":"The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors","volume":"146","author":"Rossi","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2024051415211690800_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.2020009813","article-title":"The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL","volume":"138","author":"Parikh","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2024051415211690800_bib12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"2024051415211690800_bib13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2016-07-728261","article-title":"Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients","volume":"128","author":"Gentile","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2024051415211690800_bib14","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2016-07-724740","article-title":"The CLL-IPI applied in a population-based cohort","volume":"128","author":"da Cunha-Bang","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2024051415211690800_bib15","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia International Prognostic Index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"Am J Hematol"},{"issue":"7574","key":"2024051415211690800_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"issue":"7574","key":"2024051415211690800_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"11","key":"2024051415211690800_bib18","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"issue":"12","key":"2024051415211690800_bib19","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2024051415211690800_bib20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2013-03-488197","article-title":"NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG","volume":"122","author":"Schnaiter","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2024051415211690800_bib21","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41588-022-01211-y","article-title":"Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features","volume":"54","author":"Robbe","year":"2022","journal-title":"Nat Genet"},{"issue":"3","key":"2024051415211690800_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13211","article-title":"Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia","volume":"169","author":"Ojha","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2024051415211690800_bib23","doi-asserted-by":"crossref","first-page":"E237","DOI":"10.3324\/haematol.2014.120238","article-title":"Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis","volume":"100","author":"Winkelmann","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"2024051415211690800_bib24","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2024051415211690800_bib25","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ajh.25831","article-title":"Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index","volume":"95","author":"Kleinstern","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2024051415211690800_bib26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2016.172","article-title":"Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome","volume":"31","author":"Barrio","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2024051415211690800_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2017.177212","article-title":"Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations","volume":"103","author":"Agathangelidis","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2024051415211690800_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3324\/haematol.2011.053090","article-title":"Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis","volume":"97","author":"Rasi","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"2024051415211690800_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41375-021-01344-9","article-title":"Polygenic risk score and risk of monoclonal B-cell lymphocytosis in Caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans","volume":"36","author":"Kleinstern","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2024051415211690800_bib30","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2012-02-408799","article-title":"Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans","volume":"120","author":"Coombs","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2024051415211690800_bib31","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood.2022016279","article-title":"Progression and survival of MBL: a screening study of 10 139 individuals","volume":"140","author":"Slager","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024051415211690800_bib32","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood-2013-08-523704","article-title":"Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding","volume":"123","author":"Shim","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2024051415211690800_bib33","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood-2017-11-814608","article-title":"Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis","volume":"131","author":"Kleinstern","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2118\/2224866\/blooda_adv-2023-012242-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2118\/2224866\/blooda_adv-2023-012242-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:22:01Z","timestamp":1715700121000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/9\/2118\/514977\/Tumor-mutational-load-is-prognostic-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012242","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]}}}